The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Evaluation of parameters for treatment duration of sunitinib in metastatic renal cell carcinoma.
Ellen Kossoff
No relevant relationships to disclose
Nicolas Batty
No relevant relationships to disclose
Alice C. Ceacareanu
No relevant relationships to disclose
Kristopher Attwood
No relevant relationships to disclose
Dustyn Miller
No relevant relationships to disclose
Jonathan Rabey
No relevant relationships to disclose
Charlene Lee
No relevant relationships to disclose
Ahmad Ahmad
No relevant relationships to disclose
John M. Ebos
No relevant relationships to disclose
Thomas Schwaab
No relevant relationships to disclose
Saby George
No relevant relationships to disclose
Roberto Pili
Consultant or Advisory Role - Pfizer